サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1404806

獣医腫瘍学市場の市場規模、シェア、動向分析レポート：治療別、動物タイプ別、がんタイプ別、地域別、セグメント予測、2024年～2030年

Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Radiotherapy, Surgery), By Animal Type (Canine, Feline), By Cancer Type, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 130 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
獣医腫瘍学市場の市場規模、シェア、動向分析レポート：治療別、動物タイプ別、がんタイプ別、地域別、セグメント予測、2024年～2030年
出版日: 2023年11月29日
発行: Grand View Research
ページ情報: 英文 130 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

獣医腫瘍学市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の獣医腫瘍学市場規模は2030年までに5億7,790万米ドルに達する見込みです。

2024年から2030年までのCAGRは11.29%で拡大する見込みです。ペットのがん有病率の増加と動物用診断薬の需要が予測期間中の市場を牽引すると予測されています。

がんの発生を推定するための犬がん登録の世界の採用も市場成長の促進要因です。2019年2月のfrontiers in Veterinary Scienceによると、Swiss Canine Cancer Registry（SCCR）がデータソースとして使用され、イヌとヒトのがんの将来の比較研究のために編集されました。このデータベースはさらに、ヒト集団における悪性腫瘍の発生を緩和するのに役立ち、それによって市場の成長を促進します。

獣医腫瘍学に焦点を当てた調査を行っている研究者は、獣医腫瘍学市場の成長をさらに後押ししています。例えば、2017年8月にイリノイ大学は、犬の頭頸部腫瘍の転移（体内へのがんの広がり）をより正確に検出する研究を実施しました。さらに、市場プレーヤーは新製品のイノベーションと戦略的提携にも注力しています。例えば、2018年にOasmia Pharmaceutical ABの子会社であるAdvaVetは、単一の医薬品有効成分（API）または複数のAPIを水溶性にするナノ粒子製剤ベースのXR17技術を開発しました。これは併用療法であり、ペット動物の多くのがん疾患の標準治療薬でもあります。

獣医腫瘍学市場レポートハイライト

  • コンパニオンアニマルにおけるがんの有病率の増加、ペット用がん治療薬の安全性と有効性を評価するためのいくつかの臨床試験研究、および獣医がん治療における技術的進歩は、市場の成長機会を生み出すと予想されます。
  • 化学療法は、単独または他の治療法との組み合わせで、ペットのがん治療に採用されることが増加しているため、今後数年間で最大の収益シェアを占めました。
  • 2023年に最大の収益を占めたのはイヌのセグメントで、イヌの人口が増加し、ネコに比べてイヌのがん有病率が高いです。
  • リンパ腫はコンパニオンアニマルの死亡率が高いため、2023年には他のがん種の中で市場を独占しました。2018年のVeterinary and Comparative Oncologyによると、消化管（GI）リンパ腫は犬の人口を契約する最も一般的な新生物です。
  • 北米は、有利な政府政策、企業による新製品の発売、獣医腫瘍学治療のための巨額の投資により、2023年現在、圧倒的なシェアを占めています。
  • アジア太平洋は、動物の健康と支出、がんにさらされているペット人口の増加、動物の安全性に対する政府の焦点、およびペット動物のがんの症例を抑制するためのいくつかのイニシアチブの増加に焦点を当て、有利な成長を示すと予想されます。
  • 主要企業には、ベーリンガーインゲルハイム、PetCure Oncology、Elanco、Accuray Incorporated、Varian Medical Systems、Zoetis、Karyopharm Therapeutics, Inc.One HealthおよびRegeneus Ltd.です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 獣医腫瘍学市場の変数動向と範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 付随市場の見通し
  • テクノロジー別の普及と成長の見通しマッピング、2023年
  • ユーザー視点の分析
    • 市場影響力分析
    • 主要なエンドユーザーのリスト
  • 規制の枠組み
    • 規制状況
    • 規格とコンプライアンス
  • テクノロジーのタイムライン分析
  • 獣医腫瘍学市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 業界分析- ポーターのファイブフォース分析
    • 供給企業の交渉力：中程度
    • 買い手の交渉力：低～中程度
    • 代替品の脅威：中程度
    • 新規参入業者の脅威：高
    • 競争企業間の敵対関係：高
  • 米国の獣医腫瘍学-要因別SWOT分析（政治および法律、経済、社会および技術）
    • 政治的および法的情勢
    • 経済情勢
    • 社会的情勢
    • テクノロジーの情勢
  • 新型コロナウイルスの影響分析

第4章 獣医腫瘍学市場：治療推定・動向分析

  • 治療市場シェア分析、2023年および2030年
  • 治療ダッシュボード
  • 手術
  • 放射線療法
  • 化学療法
  • 免疫療法
  • その他

第5章 獣医腫瘍学市場：動物タイプの推定・動向分析

  • 動物タイプの市場シェア分析、2023年および2030年
  • 動物タイプのダッシュボード
  • イヌ科
  • ネコ科
  • ウマ

第6章 獣医腫瘍学市場：がんタイプの推定・動向分析

  • がんの種類の市場シェア分析、2020年および2028年
  • がんの種類のダッシュボード
  • リンパ腫
  • 皮膚がん
  • 肉腫
  • その他

第7章 獣医腫瘍学市場：製品、動物タイプ、最終用途別の地域推定・動向分析

  • 地域別の獣医腫瘍学市場シェア、2023年および2030年
  • 北米
    • 北米獣医腫瘍学市場推計・予測、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州の獣医腫瘍学市場推計・予測、2018年から2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋地域
    • アジア太平洋地域の獣医腫瘍学市場推計・予測、2018年から2030年
    • 中国
    • 日本
    • インド
  • ラテンアメリカ
    • ラテンアメリカの獣医腫瘍学市場推計・予測、2018年から2030年
    • ブラジル
    • メキシコ
  • 中東とアフリカ
    • MEA獣医腫瘍学市場推計・予測、2018年から2030年
    • 南アフリカ

第8章 獣医腫瘍学市場：競合情勢

  • 市場参加の分類
  • Major Deals &Strategic Alliances Analysis
  • 企業の市況分析
  • Boehringer Ingelheim International GmbH
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Elanco
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Zoetis
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • PetCure Oncology
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Accuray Incorporated
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Varian Medical Systems, Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Nippon Zenyaku Kogyo Co. Ltd.（ZENOAQ）
    • 会社概要
    • 製品のベンチマーク
    • 戦略的取り組み
  • Morphogenesis
    • 会社概要
    • 製品のベンチマーク
    • 戦略的取り組み
  • Karyopharm
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • Regeneus Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的取り組み
  • OHC（One Health Company）
    • 会社概要
    • 製品のベンチマーク
    • 戦略的取り組み
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 List of veterinary oncology service providers
  • Table 4 North America veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 North America veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 6 North America veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 7 U.S. veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 8 U.S. veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 9 U.S. veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 10 Canada veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 11 Canada veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 12 Canada veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 13 Europe veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 14 Europe veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 15 Europe veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 16 UK veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 17 UK veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 18 UK veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 19 Germany veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 20 Germany veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 21 Germany veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 22 France veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 23 France veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 24 France veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 25 Italy veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 26 Italy veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 27 Italy veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 28 Spain veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 29 Spain veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 30 Spain veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 34 China veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 35 China veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 36 China veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 37 Japan veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 38 Japan veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 39 Japan veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 40 India veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 41 India veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 42 India veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 43 Latin America veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 44 Latin America veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 45 Latin America veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 46 Brazil veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 47 Brazil veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 48 Brazil veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 49 Mexico veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 50 Mexico veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 51 Mexico veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 52 MEA veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 53 MEA veterinary oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 54 MEA veterinary oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table 55 South Africa veterinary oncology market, by Therapy, 2018 - 2030 (USD Million)
  • Table 56 South Africa oncology market, by animal type, 2018 - 2030 (USD Million)
  • Table 57 South Africa oncology market, by cancer type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Target population & treatment rate for the U.S.
  • Fig. 10 Treatment cost analysis
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Veterinary oncology market snapshot 2023 (USD Million)
  • Fig. 13 Parent market outlook
  • Fig. 14 Ancillary market outlook
  • Fig. 15 Penetration &growth prospect mapping by Technology, 2023
  • Fig. 16 Consumer behavior analysis
  • Fig. 17 Market influencing analysis
  • Fig. 18 Technology timeline analysis
  • Fig. 19 Veterinary Oncology market dynamics
  • Fig. 20 Veterinary Oncology market driver impact
  • Fig. 21 Basic annual expenses for dog and cat owners in USD (2023)
  • Fig. 22 Veterinary Oncology market restraint impact
  • Fig. 23 Market Participation Categorization
  • Fig. 24 Company market position analysis
  • Fig. 25 Market Leaders & Innovators
  • Fig. 26 Major deals & strategic alliances analysis
  • Fig. 27 Veterinary Oncology market: Therapy movement analysis
  • Fig. 28 Veterinary Oncology Market: Therapy Dashboard
  • Fig. 29 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 30 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 31 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 32 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Veterinary Oncology market: Animal Type movement analysis
  • Fig. 35 Veterinary Oncology Market: Animal Type Dashboard
  • Fig. 36 Canine market, 2018 - 2030 (USD Million)
  • Fig. 37 Feline market, 2018 - 2030 (USD Million)
  • Fig. 38 Veterinary Oncology market: Cancer Type movement analysis
  • Fig. 39 Veterinary Oncology Market: Cancer Type Dashboard
  • Fig. 40 Lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 41 Mast cell cancer market, 2018 - 2030 (USD Million)
  • Fig. 42 Mammary and squamous cell cancer market, 2018 - 2030 (USD Million)
  • Fig. 43 Others market, 2018 - 2030 (USD Million)
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 North America veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 47 U.S. Veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 48 Canada veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 49 Europe veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 50 Germany veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 51 UK veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 52 France veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 53 Italy veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 54 Spain veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 55 Asia Pacific veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 56 China veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 57 Japan veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 58 India veterinary oncology market, 2018 - 2030 (USD million)
  • Fig. 59 Latin America veterinary oncology market, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil veterinary oncology market, 2018 - 2030 (USD Million)
  • Fig. 61 Mexico veterinary oncology market, 2018 - 2030 (USD Million)
  • Fig. 62 MEA veterinary oncology market, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa veterinary oncology market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68038-182-5

Veterinary Oncology Market Growth & Trends:

The global veterinary oncology market size is expected to reach USD 577.9 million by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 11.29% from 2024 to 2030. Increasing prevalence of cancer in pets and demand for veterinary diagnostics are projected to drive the market over the forecast period.

Adoption of canine cancer registry globally to estimate cancer incidences is another driving factor for the market growth. According to frontiers in Veterinary Science in February 2019, the Swiss Canine Cancer Registry (SCCR) was used as a data source and was compiled for future comparative studies of canine and human cancers. This database is further helpful in mitigating the incidence of malignant tumors in the human population, thereby driving the market growth.

Researchers carrying out studies focused on veterinary oncology are further boosting the veterinary oncology market growth. For instance, University of Illinois in August 2017, carried out study that involves more precise detection of metastasis (spread of cancer through the body) for head and neck tumors in dogs. Moreover, the market players are also focusing on new product innovation and strategic collaborations. For instance, in 2018 AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed XR17 technology, which is nanoparticle formulation based that makes a single Active Pharmaceutical Ingredient (API) or multiple APIs water soluble. It is a combination therapy and is also a standard treatment for a number of cancer diseases in pet animals.

Veterinary Oncology Market Report Highlights:

  • Increasing prevalence of cancer in companion animals, several clinical trial studies to evaluate the safety and effectiveness of cancer therapeutics for pets and technological advancements in veterinary oncology treatment are anticipated to create growth opportunities in the market.
  • Chemotherapy accounted for the largest revenue share over the coming years, owing to its increasing adoption for pet cancer treatment either alone or in combination with other therapies.
  • Canine segment held the largest revenue in 2023, increasing population of dogs and high prevalence of cancer in dogs as compared to cats.
  • Lymphoma dominated the market among other cancer types in 2023, due to the disease's high mortality rate in companion animals. According to the Veterinary and Comparative Oncology in 2018, Gastrointestinal (GI) Lymphoma is the most common neoplasm that contracts dog population.
  • North America held the dominant share of as of 2023, due to the favorable government policies, new product launch by the companies, and huge investment for veterinary oncology treatment.
  • Asia Pacific is anticipated to witness lucrative growth due to increasing focus on animal health and expenditure, increasing number of pet population being exposed to cancer, government focus on animal safety, and several initiatives to curb cancer cases in pet animals.
  • Some of the key companies are Boehringer Ingelheim, PetCure Oncology, Elanco, Accuray Incorporated, Varian Medical Systems, Zoetis, Karyopharm Therapeutics, Inc. One Health and Regeneus Ltd.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Target Population & Patient Stratification (Top-down estimation): mODEL 1
    • 1.6.2 Assumptions/Key Considerations
    • 1.6.3 Commodity Flow Analysis (Model 2)
  • 1.7 List of Secondary Sources
  • 1.8 Abbreviations
  • 1.9 Report Objectives

Chapter 2 Executive Summary

  • 2.1 Market Outlook, 2023
  • 2.2 Segment Outlook
  • 2.3 Competitive Outlook

Chapter 3 Veterinary Oncology Market Variables Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping by Technology, 2023
  • 3.3 User Perspective Analysis
    • 3.3.1 Market Influencer Analysis
    • 3.3.2 List of Key End Users
  • 3.4 Regulatory Framework
    • 3.4.1 Regulatory Landscape
    • 3.4.2 Standards & compliances
  • 3.5 Technology Timeline Analysis
  • 3.6 Veterinary Oncology Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Increasing prevalence and incidence of cancer in pets
      • 3.6.1.2 Growing Research and investments in pet cancer therapy
      • 3.6.1.3 Rising focus on animal safety
      • 3.6.1.4 Increasing adoption of pet insurance
      • 3.6.1.5 Technological advancements in pet cancer treatment
    • 3.6.2 Market Restraint Analysis
      • 3.6.2.1 High cost of pet cancer treatments
      • 3.6.2.2 Lack of awareness among pet owners about pet diseases
      • 3.6.2.3 Adverse effects of drugs used for pet cancer treatment
  • 3.7 Industry Analysis - Porter's
    • 3.7.1 Bargaining Power of Suppliers: Moderate
    • 3.7.2 Bargaining Power of Buyers: Low to Moderate
    • 3.7.3 Threat of Substitutes: Moderate
    • 3.7.4 Threat of New Entrants: High
    • 3.7.5 Competitive Rivalry: High
  • 3.8 U.S. Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
    • 3.8.1 Political and Legal Landscape
    • 3.8.2 Economic Landscape
    • 3.8.3 Social Landscape
    • 3.8.4 Technology Landscape
  • 3.9 Covid Impact Analysis

Chapter 4 Veterinary Oncology Market: Therapy Estimates & Trend Analysis

  • 4.1 Therapy Market Share Analysis, 2023 & 2030
  • 4.2 Therapy Dashboard
  • 4.3 Surgery
    • 4.3.1 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4 Radiotherapy
    • 4.4.1 Radiotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5 Chemotherapy
    • 4.5.1 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6 Immunotherapy
    • 4.6.1 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7 Others
    • 4.7.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Veterinary Oncology Market: Animal Type Estimates & Trend Analysis

  • 5.1 Animal Type Market Share Analysis, 2023 & 2030
  • 5.2 Animal Type Dashboard
  • 5.3 Canine
    • 5.3.1 Canine market estimates and forecasts, 2018 - 2030 (USD million)
  • 5.4 Feline
    • 5.4.1 Feline market estimates and forecasts, 2018 - 2030 (USD million)
  • 5.5 Equine
    • 5.5.1 Equine market estimates and forecasts, 2018 - 2030 (USD million)

Chapter 6 Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

  • 6.1 Cancer Type Market Share Analysis, 2020 & 2028
  • 6.2 Cancer Type Dashboard
  • 6.3 Lymphoma
    • 6.3.1 Lymphoma market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4 Skin Cancers
    • 6.4.1 Skin Cancers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5 Sarcomas
    • 6.5.1 Sarcomas market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 Other market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Veterinary Oncology Market: Regional Estimates & Trend Analysis by Product, Animal Type, and End-Use

  • 7.1 Veterinary Oncology Market Shares By Region, 2023 & 2030
  • 7.2 North America
    • 7.2.1 North America Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Germany
      • 7.3.2.1 Germany Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 UK
      • 7.3.3.1 UK Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 France
      • 7.3.4.1 France Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 Italy
      • 7.3.5.1 Italy Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 Spain
      • 7.3.6.1 Spain Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 China Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Japan
      • 7.4.3.1 Japan Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 India
      • 7.4.4.1 India Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6 Middle East & Africa
    • 7.6.1 MEA Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 SOuth Africa Veterinary Oncology market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8 Veterinary Oncology Market: Competitive Landscape

  • 8.1 Market Participation Categorization
  • 8.2 Major Deals & Strategic Alliances Analysis
  • 8.3 Company market position analysis
  • 8.4 Boehringer Ingelheim International GmbH
    • 8.4.1 Company overview
    • 8.4.2 Financial performance
    • 8.4.3 Product benchmarking
    • 8.4.4 Strategic initiatives
  • 8.5 Elanco
    • 8.5.1 Company overview
    • 8.5.2 Financial performance
    • 8.5.3 Product benchmarking
    • 8.5.4 Strategic initiatives
  • 8.6 Zoetis
    • 8.6.1 Company overview
    • 8.6.2 Financial performance
    • 8.6.3 Product benchmarking
    • 8.6.4 Strategic initiatives
  • 8.7 PetCure Oncology
    • 8.7.1 Company overview
    • 8.7.2 Financial performance
    • 8.7.3 Product benchmarking
    • 8.7.4 Strategic initiatives
  • 8.8 Accuray Incorporated
    • 8.8.1 Company overview
    • 8.8.2 Financial performance
    • 8.8.3 Product benchmarking
    • 8.8.4 Strategic initiatives
  • 8.9 Varian Medical Systems, Inc.
    • 8.9.1 Company overview
    • 8.9.2 Financial performance
    • 8.9.3 Product benchmarking
    • 8.9.4 Strategic initiatives
  • 8.10 Nippon Zenyaku Kogyo Co. Ltd. (ZENOAQ)
    • 8.10.1 Company overview
    • 8.10.2 Product benchmarking
    • 8.10.3 Strategic initiatives
  • 8.11 Morphogenesis
    • 8.11.1 Company overview
    • 8.11.2 Product benchmarking
    • 8.11.3 Strategic initiatives
  • 8.12 Karyopharm
    • 8.12.1 Company overview
    • 8.12.2 Financial performance
    • 8.12.3 Product benchmarking
    • 8.12.4 Strategic initiatives
  • 8.13 Regeneus Ltd.
    • 8.13.1 Company overview
    • 8.13.2 Financial performance
    • 8.13.3 Product benchmarking
    • 8.13.4 Strategic Initiatives
  • 8.14 OHC (One Health Company)
    • 8.14.1 Company overview
    • 8.14.2 Product benchmarking
    • 8.14.3 Strategic Initiatives